Author Correction: PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein. - Thura M; Al-Aidaroos AQ; Gupta A; Chee CE; Lee SC; Hui KM; Li J; Guan YK; Yong WP; So J; Chng WJ; Ng CH; et al. (Nature communications, 2021)